Want to Join Our Team?
Learn about Blue Matter's innovative work experiences, enriching development opportunities, team-oriented "People First" culture, and a lot more.
Insights
Access our ever-expanding library of thought leadership resources for strategic leaders and professionals in biopharma. It’s full of useful content addressing industry challenges, best practices, therapeutic markets, innovative ideas, and forward-looking insights.
Featured eBook
The “Best Practice Organization” and Its Importance for Success in Today’s Biopharma Industry
Learn More >
Whitepaper
Adding (Ultra-) Rare Disease Therapies to Your Company’s Portfolio: It’s a Whole New “Ball Game”
Whitepaper
Breakfast Club “Bottom Line” #13: What does patient centricity look like from a patient perspective?
Infographic
When Rare Diseases Don’t Get Rare Attention
Whitepaper
Summary of Blue Matter Breakfast Club #12: How To Build a Great Company Culture Through Effective (Virtual) Engagement
Infographic
Quick Take: Adeno-Associated Virus (AAV) Vectors in Rare Diseases
Whitepaper
Summary of Blue Matter Breakfast Club #10: Patient Identification in Rare Diseases
Whitepaper
Spinal Muscular Atrophy: Outlook and Implications for Biopharma (Part 2)
Whitepaper
Spinal Muscular Atrophy: A Rare Disease with a Complex Treatment Landscape (Part 1)
Whitepaper
Summary of Blue Matter Breakfast Club #9: Is Patient Centricity Always Critical?
Whitepaper
Beyond Linear Drug Development: Leveraging the Constellation Approach in Rare Diseases
Blog
Beyond Linear Drug Development: Leveraging the Constellation Approach in Rare Diseases
Whitepaper
Summary of Blue Matter Breakfast Club #8: How can a company focused on rare diseases optimize its customer-facing teams?
Blog
Key Themes from the 2021 Virtual World Orphan Drug Congress
Whitepaper
Success in Rare Diseases, Part V: Working with Payers in the Rare Disease Ecosystem
Blog
Success in Rare Diseases, Part V: Working with Payers in the Rare Disease Ecosystem
Whitepaper
Success in Rare Diseases, Part IV: Successfully Implementing Clinical Trials in the Rare Disease Ecosystem
